Detalhe da pesquisa
1.
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Nature
; 600(7890): 727-730, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34912120
2.
Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
Cancer
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38781433
3.
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Lancet
; 402(10418): 2197-2208, 2023 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871604
4.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Lancet
; 402(10408): 1133-1146, 2023 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499670
5.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(11): 1181-1195, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875143
6.
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Int J Cancer
; 152(4): 749-760, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36121651
7.
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
BMC Med
; 21(1): 173, 2023 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37147645
8.
Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase.
Immunopharmacol Immunotoxicol
; 45(3): 355-369, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36476048
9.
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
JAMA
; 330(21): 2064-2074, 2023 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38051328
10.
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.
Chin J Cancer Res
; 35(5): 526-535, 2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37969958
11.
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Cancer
; 128(5): 995-1003, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878659
12.
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers.
Oncologist
; 2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445725
13.
A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
Future Oncol
; 18(22): 2413-2424, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35674480
14.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Lancet Oncol
; 22(7): 977-990, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143971
15.
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Lancet Oncol
; 22(8): 1081-1092, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34252374
16.
Pyroptosis, a new bridge to tumor immunity.
Cancer Sci
; 112(10): 3979-3994, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34252266
17.
A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
Cancer
; 127(21): 3975-3984, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34355801
18.
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Oncologist
; 26(10): e1693-e1703, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34105207
19.
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
BMC Gastroenterol
; 21(1): 398, 2021 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34688250
20.
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
Gastric Cancer
; 24(4): 913-925, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33945049